You just don’t understand this stuff MA … imo… Passing a...

You just don’t understand this stuff MA … imo…

Passing a futility test is a good thing. The more times you pass a futility test the better your odds of a positive outcome are.

Passing a DMC review without modification is a good thing because it indicates that trial assumptions are proving valid. This is a good thing because the less fiddling required the better for ultimate positive outcome.

But beside all that shareholders of companies conducting clinical trials by a vast majority wish to be updated on progress. The more information and updates the better.

And the reverse operates. Investors can be skittish. They worry about what the company is not telling them. No news in this space nearly always means bad news.

The criticality here is getting to triviality.

I don’t follow MSB closely enough to keep up with latest twists and turns. But I thought the plan was that the P3 CHF trial was split after Teva walked into two parallel trials of 600 subject each. So what happened to the other trial? Money where your mouth is for MSB with respect to that other trial is quite informative I suspect.